Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Cancer Biology & Therapy|February 27, 2009
hBub1 deficiency triggers a novel p53 mediated early apoptotic checkpoint pathway in mitotic spindle damaged cellsFangming Gao, Jose F Ponte, Panagiotis Papageorgis, et al.
Neoplasia (New York, N.Y.)|July 29, 2017
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma ModelsStuart W Hicks, Katharine C Lai, L Cristina Gavrilescu, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|February 18, 2005
Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary reportHamid Mostafavi Abdolmaleky, Kuang-hung Cheng, Andrea Russo, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2019
Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs)Emily E Reid, Katie E Archer, Manami Shizuka, et al.
Molecular Cancer Therapeutics|November 12, 2020
Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase <i>In Vivo</i> EfficacyJose F Ponte, Leanne Lanieri, Eshita Khera, et al.
Cancer|April 26, 2017
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumorsKathleen N Moore, Hossein Borghaei, David M O'Malley, et al.
Bioconjugate Chemistry|May 14, 2016
Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid ConjugatesJose F Ponte, Xiuxia Sun, Nicholas C Yoder, et al.
ACS Medicinal Chemistry Letters|August 16, 2019
Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs)Katie E Archer, Emily E Reid, Manami Shizuka, et al.
Human Molecular Genetics|September 21, 2006
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorderHamid Mostafavi Abdolmaleky, Kuang-Hung Cheng, Stephen V Faraone, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|July 27, 1999
Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III studyP E Gallenga, L Lobefalo, L Colangelo, et al.
Pageof 7